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Polypharmacy in older people: time to take action 
Medication is the most used medical intervention to improve health. However, in 
the older patient the prescription of medication becomes a complex task that poses a 
challenge for the clinician. Changes in pharmacokinetics and pharmacodynamics 
associated with age, the exclusion of older patients in clinical trials and their consequent 
underrepresentation in clinical practice guidelines, high multimorbidity and other 
factors that influence the prognosis and management of these patients, such as frailty, 
dementia or limited life expectancy will condition the use of medications in older 
patients. Polypharmacy is highly prevalent in this population, due to the accumulation 
of chronic diseases and the presence of multiple prescribers. The important problems 
resulting from this polypharmacy are already well known, due to its association with an 
increased risk of adverse effects, drug-drug interactions, poor treatment adherence, 
more hospitalizations, higher mortality and increased costs[1]. 
Population aging leads to a progressive increase in older patients in all healthcare 
settings and medical specialties. Knowing the complexity and risks associated with 
polypharmacy, it is the responsibility of all professionals to be involved in the adequate 
care of the older patient and the proper management of their medication. There has been 
progress in recent years in this regard, but it is time for all of us to take action; what is 
the next step? 
From a global perspective, given the complexity and differential characteristics 
in older patients, we must take into account the paradigm shift of the end of the disease 
era: medical care focused on the diagnosis and treatment of individual diseases is “at 
best out of date and at worst harmful”. The time has come to abandon the disease as the 
primary focus of medical care and to place frailty and function at the centre of care 
models[2]. This idea is no longer a theory, but a real and pressing need. In the same way, 
polypharmacy and the associated negative effects are no more than a consequence of the 
traditional model of care based on a disease-centered approach.  Aging will occupy 
increasingly wider and relevant positions in most disciplines and medical specialties, 
which makes it necessary for all of them to begin to take this change of vision, and to be 
impregnated with some geriatric concepts, such as frailty and comprehensive geriatric 
assessment. This, of course, must be translated into one of the main tools for the 
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prevention and improvement of health: medicines. Beyond the acute or chronic 
pathology on which we want to intervene, we must look at the whole picture, since all 
factor are related: not only the patients’ antecedents and medical problems, but also 
their functional, cognitive, affective or social situation, their geriatric syndromes, the 
rest of its pharmacological and non-pharmacological treatment, the patients' 
expectations, their frailty status and quality of life, and the individual risks and 
therapeutic goals. As an example, frailty and prefrailty have shown to be associated 
with polypharmacy[3]. In older persons it is particularly relevant that we consider 
polypharmacy before prescribing a drug agent. It is imperative that we take into account 
drug-drug interactions, therapeutic cascades, frequent adverse effects (such as falls or 
delirium) or the potentially inappropriate medications. Other objectives of adequate 
drug prescribing include identification of medication risks and adverse effects, prioritize 
the most important problems and make treatment targets more flexible. It is also 
necessary to keep in mind that patients may have different preferences, attitudes to 
medicines, experience of burden of treatment and own therapeutic goals, and they have 
the right to be involved in decision making on drug treatment. 
 
 Knowing how to analyse all this information adequately and integrate it to 
include it in decision-making on medication prescribing is a complex task that requires 
investing time, continuously updating knowledge and improving teamwork. The 
multidisciplinary work must be an essential piece when addressing polypharmacy and 
the appropriate use of medications in older adults. Even being aware and being prepared 
for the challenges of polypharmacy and the prescription of medicines in older adults, in 
many cases the collaboration of specialized professionals will be beneficial. Two clear 
examples would be the participation of a geriatrician who makes a geriatric 
comprehensive assessment and conducts an individualized therapeutic plan according to 
the needs of the patient, and a clinical pharmacist, who can make an exhaustive 
medication review and advice on pharmacological aspects and medication adherence[4]. 
 
 In cases where patient management is carried out without the collaboration of 
these professionals, it would be advisable to at least know certain tools that can help us 
make better decisions about drug prescribing, and include them in our daily practice, 
our computer systems, etc. The main instruments to optimize pharmacological treatment 
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in the older patients have been classically divided into explicit tools, which are lists 
based on criteria of potentially inappropriate medications in older people such as the 
STOPP/START criteria[5], and implicit criteria and tools, based on clinical judgments, 
which propose simple questionnaires or algorithms to help improving medication 
appropriateness[6]. In addition, as the number of medications is the most significant 
predictor of the inappropriate use of drugs, deprescription has been proposed as a 
possible solution to address this problem. It has been described as the process of 
withdrawal of an inappropriate medication, supervised by a health care professional 
with the goal of managing polypharmacy and improving outcomes[7]. Other recent 
tools have focused on the adequate use of medications in older patients with limited life 
expectancy or at the end of life, situations that can be especially complex[8, 9]. 
 
 Finally, we must pay attention to the problems of medication reconciliation 
derived from the transitions of care, like hospital admission and discharge or nursing 
home admission, and the presence of different prescribers. Medication reconciliation is 
the process of obtaining and documenting a complete and accurate list of current patient 
medications and comparing this list with medication orders at each point of care 
transition to identify and rectify any discrepancies before patient harm occurs, and 
should be implemented in transitions of care, especially in patients with 
polypharmacy[10]. Processes and tools should also be adapted for this purpose [11]. 
 
 In summary, the management of polypharmacy in older patients involves a 
paradigm shift that abandons the disease as the axis of health care towards an integral 
approach linked to multidisciplinary work, dedication and specific preparation for 
medication prescribing in these patients, and a focus on medication reconciliation in 
transitions of care. Knowing how to face the challenge of polypharmacy and its 
consequences for patients, healthcare systems and society is everyone's responsibility, 
and its success will depend on the involvement of all professionals. 
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